RBC Capital Remains a Hold on Gilead Sciences (GILD)
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with ...
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results.
PMLiVE2d
Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults
Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to ...
FDA beats EMA to most approved new drugs in 2024
The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs ...
The Pharma Letter6d
CymaBay’s Livdelzi approved by MHRA
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today, approved Livdelzi (seladelpar), developed by ...
Seladelpar approved to treat adult patients in the U.K. with liver illness
The Medicines and Healthcare products Regulatory Agency has approved the medicine seladelpar in adults for the treatment of a liver illness ...
BioSpace9d
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...
Healio14d
Cour Pharmaceuticals snags orphan drug designation for CNP-104 for the treatment of PBC
The FDA has granted Cour Pharmaceuticals orphan drug designation for CNP-104, a biodegradable nanoparticle in development for the treatment of primary biliary cholangitis, the company announced in a ...